7,654 Shares in Celcuity, Inc. $CELC Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 7,654 shares of the company’s stock, valued at approximately $763,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CELC. Apis Capital Advisors LLC acquired a new stake in shares of Celcuity during the third quarter worth about $38,334,000. UBS Group AG lifted its holdings in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after purchasing an additional 769,891 shares during the period. Deerfield Management Company L.P. acquired a new stake in shares of Celcuity during the third quarter worth about $36,236,000. Alliancebernstein L.P. lifted its holdings in shares of Celcuity by 2,208.6% during the third quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock worth $32,241,000 after purchasing an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. lifted its holdings in shares of Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after purchasing an additional 437,696 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CELC. HC Wainwright decreased their target price on Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $157.00 target price on shares of Celcuity in a report on Friday, May 15th. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research report on Thursday, May 28th. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Finally, Wells Fargo & Company reduced their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and a consensus price target of $152.09.

Insider Activity at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 37,000 shares of company stock valued at $5,111,950. 13.33% of the stock is owned by company insiders.

Celcuity Stock Down 4.7%

Shares of CELC stock opened at $88.24 on Thursday. The stock has a 50 day moving average of $120.79 and a 200 day moving average of $111.44. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market cap of $4.30 billion, a P/E ratio of -22.63 and a beta of 0.10. Celcuity, Inc. has a twelve month low of $11.27 and a twelve month high of $151.02.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, sell-side analysts expect that Celcuity, Inc. will post -3.69 EPS for the current year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.